Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asfandyar Mufti

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Journal of Cutaneous Medicine and Surgery|September 3, 2024
Cutaneous Granulomatous Reactions in Patients Treated with Immune Checkpoint Inhibitors: A Systematic ReviewNawar Tarafdar, Muskaan Sachdeva, Iryna Savinova, et al.
The Journal of Dermatological Treatment|April 21, 2022
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort studyBrian D Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Journal of Cutaneous Medicine and Surgery|June 5, 2026
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination TherapySiddhartha Sood, Ahmed Bagit, Khalad Maliyar, et al.
Journal of the American Academy of Dermatology|April 27, 2024
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort studyAhmed Bagit, Khalad Maliyar, Mark Mansour, et al.
Journal of Cutaneous Medicine and Surgery|September 3, 2024
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort StudyAhmed Bagit, Khalad Maliyar, Mark Mansour, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|December 22, 2016
Patch Test Reactions to Corticosteroids: Retrospective Analysis From the North American Contact Dermatitis Group 2007-2014Melanie D Pratt, Asfandyar Mufti, Jennifer Lipson, et al.
Dermatology and Therapy|January 23, 2026
Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective StudyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Clinical and Experimental Dermatology|July 29, 2025
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective studyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 11, 2024
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort studyAndrea Chiricozzi, Giulia Coscarella, Luis Puig, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Journal of Cutaneous Medicine and Surgery|September 3, 2024
Cutaneous Granulomatous Reactions in Patients Treated with Immune Checkpoint Inhibitors: A Systematic ReviewNawar Tarafdar, Muskaan Sachdeva, Iryna Savinova, et al.
The Journal of Dermatological Treatment|April 21, 2022
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort studyBrian D Rankin, Jorge-Ryan Georgakopoulos, Muskaan Sachdeva, et al.
Journal of Cutaneous Medicine and Surgery|June 5, 2026
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination TherapySiddhartha Sood, Ahmed Bagit, Khalad Maliyar, et al.
Journal of the American Academy of Dermatology|April 27, 2024
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort studyAhmed Bagit, Khalad Maliyar, Mark Mansour, et al.
Journal of Cutaneous Medicine and Surgery|September 3, 2024
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort StudyAhmed Bagit, Khalad Maliyar, Mark Mansour, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|December 22, 2016
Patch Test Reactions to Corticosteroids: Retrospective Analysis From the North American Contact Dermatitis Group 2007-2014Melanie D Pratt, Asfandyar Mufti, Jennifer Lipson, et al.
Dermatology and Therapy|January 23, 2026
Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective StudyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
Clinical and Experimental Dermatology|July 29, 2025
Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective studyTiago Torres, Siddhartha Sood, Orhan Yilmaz, et al.
American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 11, 2024
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort studyAndrea Chiricozzi, Giulia Coscarella, Luis Puig, et al.
Pageof 15